Eleven Biotherapeutics Inc. (EBIO) Trading Up 6.3%
Eleven Biotherapeutics Inc. (NASDAQ:EBIO) shares were up 6.3% on Monday . The stock traded as high as $5.17 and last traded at $5.08, with a volume of 1,014,774 shares traded. The stock had previously closed at $4.78.
The stock’s market capitalization is $76.97 million. The company has a 50 day moving average price of $3.45 and a 200 day moving average price of $1.54.
Eleven Biotherapeutics (NASDAQ:EBIO) last released its quarterly earnings results on Friday, August 12th. The biopharmaceutical company reported ($0.33) EPS for the quarter. Equities analysts forecast that Eleven Biotherapeutics Inc. will post ($1.75) earnings per share for the current year.
In other Eleven Biotherapeutics news, major shareholder Boxer Capital, Llc sold 1,042,000 shares of the company’s stock in a transaction on Monday, June 13th. The stock was sold at an average price of $2.74, for a total transaction of $2,855,080.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Eleven Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. The Company designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.